Blueprint Medicines Corporation (0HOJ.L)
USD 97.85
(1.4%)
USD 97.85
(1.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 236.58 Million USD | 20.78% |
| 2022 | 186.22 Million USD | 14.85% |
| 2021 | 162.14 Million USD | -79.56% |
| 2020 | 793.31 Million USD | 1092.73% |
| 2019 | 66.51 Million USD | 133.41% |
| 2018 | -199.1 Million USD | -61.53% |
| 2017 | -123.26 Million USD | -131.0% |
| 2016 | -53.35 Million USD | -43.48% |
| 2015 | -37.18 Million USD | -16.78% |
| 2014 | -31.84 Million USD | -99.92% |
| 2013 | -15.92 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 126.25 Million USD | -0.55% |
| 2024 Q1 | 88.11 Million USD | 25.58% |
| 2024 Q2 | 126.94 Million USD | 44.07% |
| 2023 Q4 | 70.16 Million USD | 34.9% |
| 2023 FY | 224.91 Million USD | 20.78% |
| 2023 Q1 | 60.11 Million USD | 77.15% |
| 2023 Q2 | 55.24 Million USD | -8.09% |
| 2023 Q3 | 52.01 Million USD | -5.85% |
| 2022 Q1 | 57.65 Million USD | -42.04% |
| 2022 FY | 186.22 Million USD | 14.85% |
| 2022 Q2 | 31.66 Million USD | -45.08% |
| 2022 Q4 | 33.93 Million USD | -46.12% |
| 2022 Q3 | 62.97 Million USD | 98.91% |
| 2021 Q4 | 99.47 Million USD | 387.66% |
| 2021 Q1 | 21.47 Million USD | -36.8% |
| 2021 Q2 | 20.8 Million USD | -3.13% |
| 2021 Q3 | 20.39 Million USD | -1.94% |
| 2021 FY | 162.14 Million USD | -79.56% |
| 2020 FY | 793.31 Million USD | 1092.73% |
| 2020 Q4 | 33.97 Million USD | -95.44% |
| 2020 Q3 | 744.97 Million USD | 8967.33% |
| 2020 Q2 | 8.21 Million USD | 33.75% |
| 2020 Q1 | 6.14 Million USD | 116.55% |
| 2019 Q2 | -81.99 Million USD | -11.52% |
| 2019 Q3 | -72.31 Million USD | 11.8% |
| 2019 Q4 | -37.11 Million USD | 48.68% |
| 2019 FY | 66.51 Million USD | 133.41% |
| 2019 Q1 | -73.52 Million USD | -5.79% |
| 2018 Q1 | -49 Million USD | -16.66% |
| 2018 Q2 | -17.13 Million USD | 65.03% |
| 2018 Q3 | -63.46 Million USD | -270.42% |
| 2018 Q4 | -69.49 Million USD | -9.5% |
| 2018 FY | -199.1 Million USD | -61.53% |
| 2017 Q3 | -31.23 Million USD | -14.06% |
| 2017 Q2 | -27.38 Million USD | -20.9% |
| 2017 Q1 | -22.64 Million USD | -38.24% |
| 2017 FY | -123.26 Million USD | -131.0% |
| 2017 Q4 | -42 Million USD | -34.48% |
| 2016 Q4 | -16.38 Million USD | -36.63% |
| 2016 Q3 | -11.99 Million USD | 15.61% |
| 2016 Q2 | -14.2 Million USD | -31.81% |
| 2016 FY | -53.35 Million USD | -43.48% |
| 2016 Q1 | -10.77 Million USD | 8.62% |
| 2015 Q3 | -8.25 Million USD | 3.52% |
| 2015 FY | -37.18 Million USD | -16.78% |
| 2015 Q2 | -8.55 Million USD | 0.28% |
| 2015 Q4 | -11.79 Million USD | -42.9% |
| 2015 Q1 | -8.58 Million USD | 24.29% |
| 2014 FY | -31.84 Million USD | -99.92% |
| 2014 Q1 | -5.38 Million USD | 0.0% |
| 2014 Q3 | -8.36 Million USD | -23.75% |
| 2014 Q4 | -11.33 Million USD | -35.43% |
| 2014 Q2 | -6.76 Million USD | -25.66% |
| 2013 FY | -15.92 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 337.706% |
| Dynavax Technologies Corporation | 182.11 Million USD | -29.908% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 54.828% |
| Perrigo Company plc | 1.68 Billion USD | 85.921% |
| Illumina, Inc. | 2.74 Billion USD | 91.378% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 98.446% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 2573.176% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.108% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 95.484% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -2255.945% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 97.907% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 1300.995% |
| Waters Corporation | 1.76 Billion USD | 86.567% |
| Biogen Inc. | 7.3 Billion USD | 96.76% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 621.972% |
| Evolus, Inc. | 140.52 Million USD | -68.356% |
| Adicet Bio, Inc. | -6.09 Million USD | 3979.698% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -1499.189% |
| bluebird bio, Inc. | -4.03 Million USD | 5970.571% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -223.79% |
| FibroGen, Inc. | 128.9 Million USD | -83.535% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 93.172% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 859.069% |
| Homology Medicines, Inc. | -7.22 Million USD | 3372.707% |
| Geron Corporation | -123.5 Million USD | 291.561% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 84.414% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 34.651% |
| Myriad Genetics, Inc. | 476.4 Million USD | 50.339% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 81121.918% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 159.325% |
| Zoetis Inc. | 5.83 Billion USD | 95.945% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -78239.073% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 89.093% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 87.577% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 97.251% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 78180.528% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 69.611% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 75685.942% |
| Verastem, Inc. | -62 Thousand USD | 381687.097% |
| Nektar Therapeutics | 53.47 Million USD | -342.395% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 3.251% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 377.629% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 78.354% |
| OPKO Health, Inc. | 318.12 Million USD | 25.632% |
| Exelixis, Inc. | 1.75 Billion USD | 86.54% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 87.194% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 50.286% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -10580.993% |
| Imunon, Inc. | -720 Thousand USD | 32958.661% |
| Insmed Incorporated | 239.63 Million USD | 1.273% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 62.853% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1266.037% |
| TG Therapeutics, Inc. | 219.1 Million USD | -7.976% |
| Incyte Corporation | 3.44 Billion USD | 93.124% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 31.206% |